Background: We established the cell cycle profiling (C2P) assay for specific activity (SA; activity/expression) of cyclin-dependent kinases (CDKs). C2P risk score (C2P-RS) based on CDK1 and CDK2 SAs was significantly associated with relapse in breast cancer (BC). This study was conducted to investigate the predictive value of C2P-RS for neoadjuvant chemotherapy (NAC).
introduction
For the past two decades, adjuvant systemic chemotherapy, which provides great clinical benefits in patients with a high risk of relapse, has increasingly been used in early breast cancer (BC) [1] . However, in many patients, in particular those with a low or intermediate risk of relapse, such therapy has yielded no or little benefit and has led to adverse effects [2] . Therefore, useful predictive factors are needed to identify patients who can benefit from such chemotherapy.
Proliferation reflects tumour aggressiveness and plays a key role among the many mechanisms involved in tumour progression [3] [4] [5] . Many studies have demonstrated that proliferation markers, e.g. mitotic index, DNA flow cytometry, [ 3 H]thymidine uptake, cyclin E and Ki-67 expression, have significant prognostic and predictive values in BCs [3] [4] [5] [6] [7] [8] [9] . None of these markers, however, has been established as a routine laboratory test. Even in the case of Ki-67 expression, which is the most widely used proliferation marker, a few problems remain unresolved, i.e. cut-off points and interobserver or interassay variations [9, 10] .
We developed a novel proliferation assay, termed cell cycle profiling (C2P), to measure not only the expression but also the activity of cyclin-dependent kinase (CDK) 1 and CDK2, which play a pivotal role in cell cycle regulation [11] . It was found that the CDK-based risk derived from CDK1-specific activity (SA; activity/expression), CDK2 SA and the ratio of CDK2 SA to CDK1 SA had a significant prognostic impact on Japanese BC patients with or without lymph node involvement (pilot study carried out at a single institute, N = 284) [12] . This CDK-based risk was used to classify another cohort of Japanese patients without lymph node involvement (retrospective study on a multicentre basis, N = 233) into high-and low-risk groups with a significant difference in 5-year relapse rates (data not shown). Furthermore, we devised the C2P risk score (C2P-RS) based on the reanalysis of the data of the retrospective study, to improve risk categorisation [13] . In that study, the classification of patients who had no lymph node involvement, were hormone receptor positive and received only endocrine therapy as a systemic adjuvant treatment into three categories according to C2P-RS (high, intermediate and low C2P-RS) revealed that those in the high-C2P-RS group had a significantly lower relapse-free survival rate at 5 years than those in the low-C2P-RS group (84.0% versus 96.5%, P = 0.009). The prognostic value of the significant association between C2P-RS and relapse was validated in a Dutch cohort [13] .
The aim of this study was to evaluate the predictive implications of C2P-RS regarding the response to neoadjuvant chemotherapy (NAC) in early BCs. As C2P-RS represents tumour proliferation, we hypothesised that tumours with high C2P-RS are likely to show a good response to chemotherapy.
patients and methods , q3w, four cycles) (P-FEC). Written informed consent was obtained from all patients and the institutional review board of each hospital approved this study.
assay for C2P-RS CDK1 and CDK2 SAs were determined via the C2P assay using frozen tissue samples obtained by core needle biopsy before NAC. Subsequently, C2P-RS was calculated using the following formula, which was modified from a formula described previously because of the alteration of the learning cohort [13] .
C2P À RS = Eq: ð1Þ · Eq: ð2Þ · 3000 ð1Þ 0:15=ð1+Expf2ðx21:6Þ·7gÞ; where x = logðCDK1 SAÞ ð2Þ 0:25=ð1+Expf2ðy21:0Þ·6gÞ; where y = logðCDK2 SA=CDK1 SAÞ Tumours were divided into three categories (high, intermediate and low RS groups) according to C2P-RS and CDK1 SA using the prefixed cut-off points, which were the same as those reported previously, i.e. high RS was defined as C2P-RS ‡ 1.47 or CDK1 SA ‡ 90 maU/eU, low RS as C2P-RS < 0.45 and CDK1 SA < 70 maU/eU, and intermediate RS as the area between high and low RS (Figure 1 ) [13] .
expression of hormone receptors, Ki-67 and human epidermal growth factor receptor 2
The expression of the estrogen receptor (ER), progesterone receptor (PR) and Ki-67 in tumour samples from core needle biopsy before NAC was determined by immunohistochemistry (IHC), as reported previously [14] . The cut-off values were 10% for ER and PR and 20% for Ki-67, which is an optimal point for the discrimination of tumours with or without pathological complete response (pCR). Expression of the human epidermal growth factor receptor 2 (HER2) was examined using IHC (HercepTest; Dako Corp., Carpinteria, CA) or FISH (PathVysion; Vysis Inc., Downers Grove, IL). Tumours that were positive for this IHC (3+) or FISH (+) were considered HER2 positive.
evaluation of the clinical and pathologically documented response to chemotherapy
The clinical responses of primary BCs to paclitaxel and P-FEC were evaluated based on the reduction rate of the tumour area, measured using dynamic magnetic resonance imaging before and after paclitaxel administration and after the completion of P-FEC. Patients with a reduction rate ‡80% were considered responders, as tumours showing a good response (reduction rate ‡80%) to paclitaxel are likely to attain pCR after P-FEC [15] . pCR was defined as the absence of residual invasive foci and of lymph node involvement and was evaluated using tissue samples from operations carried out after P-FEC.
statistical methods
Relationships between clinicopathological parameters, Ki-67 or C2P-RS, and clinical or pathologically documented response (pathological response) were calculated using the chi-square test. A logistic regression model was used for both univariate and multivariate analyses. Test results were considered significant when P £ 0.05. Figure 1 . Cell cycle profiling (C2P) map in patients, used for pathological complete response (pCR) evaluation. The C2P risk score (RS) of patients (n = 122), used for pCR evaluation, is shown. The high-C2P-RS group was defined as having C2P-RS ‡ 1.47 or CDK1 SA ‡ 90 maU/eU (black line), the low-C2P-RS group was defined as having C2P-RS < 0.45 and CDK1 SA < 70 maU/eU (dotted line) and the intermediate group was defined as being between the high and the low groups. K1 and K2 zones were defined as areas for the cases with activity of CDK1 or CDK2 less than the detection limit and with both the expressions in quantitative range of a C2P assay. LA zone was for the cases with both the activities less than the detection limit and with both the expressions in quantitative range of the assay. Cases in K1, K2 and LA zones are considered to be included in the low-C2P-RS group. Closed circle, non-pCR; closed circle with an outer ring: pCR. 
patient characteristics and response to chemotherapy
One hundred and eighty-one patients were enrolled in this study (Osaka University Hospital, 173 patients; Osaka Koseinenkin Hospital, 8 patients). Of these, 23 individuals (12.7%) were excluded from this study based on the lack of informative results for the C2P assay (low CDK1 and/or CDK2 expression, 19 patients; assay failure, 3 patients; blood contamination, 1 patient). A further 34 patients were excluded for clinical reasons (11 did not receive NAC, 7 had stage IV disease, 5 were treated with other chemotherapy regimens, 6 stopped receiving paclitaxel early because of adverse effects, 3 had inflammatory BC and 2 refused to receive NAC continuously). The remaining 124 patients, whose characteristics are shown in Table 1 , were eligible for assessment in this study [16] .
Fifty-five (44%) of the 124 patients showed a good response to paclitaxel (reduction rate ‡80%) and 69 (56%) were nonresponders (reduction rate <80%). Two patients were excluded from the analysis of clinical and pathological response to P-FEC because they did not receive FEC. Finally, 122 patients were eligible for the assessment of pCR in this study, and 22 (18%) of them attained pCR after P-FEC.
relationship between C2P-RS and other clinicopathological factors and clinical response to paclitaxel or P-FEC
The population of each C2P-RS category was 56 (45%) patients with high C2P-RS, 22 (18%) patients with intermediate C2P-RS and 46 (37%) patients with low C2P-RS. Regarding the relationships between C2P-RS and clinicopathological factors, C2P-RS had no significant relationship with age, tumour size, ER, PR or HER2 status. However, tumours with high or intermediate C2P-RS were likely to exhibit high histological grade ( Table 2 ). The association between C2P-RS and Ki-67 expression evaluated with the chi-square test was significant (P = 0.006; Table 2 ), but that evaluated with the Spearman's rank correlation method was significant but weak (P = 0.001, R 2 = 0.025). Classification based on C2P-RS showed a significant correlation with clinical response to paclitaxel, i.e. 42 (54%) of 78 patients in the high + intermediate group were responders compared with 13 (28%) of 46 patients in the low group (P = 0.003). Furthermore, in response to P-FEC, a significant number of patients in the high + intermediate group (58 of 77 patients, 75%) exhibited a good clinical response compared with the low group (24 of 45 patients, 53%; P = 0.017).
relationship between pCR and clinicopathological parameters or C2P-RS Among the clinicopathological parameters, age, tumour size and histological grade were not significantly associated with pCR. However, negative ER or PR and positive HER2 status were significantly associated with high pCR rates compared with positive ER or PR and negative HER2 status, respectively (ER: 30% versus 9%, P = 0.003; PR: 25% versus 6%, P = 0.008; HER2: 34% versus 11%, P = 0.003). Tumours were classified into the four subtypes according to ER, PR and HER2: luminal A (ER+/PR+/HER22), luminal B (ER+/PR+/HER2+, ER+/ PR2/HER2 any or ER2/PR+/HER2 any), HER2 (ER2/PR2/ HER2+) and triple negative (ER2/PR2/HER22). HER2 subtype showed significantly higher pCR rates (43%) than triple negative (20%), luminal B (14%) or luminal A (5%) subtype (Table 3) . Tumours with high Ki-67 expression were significantly likely to attain pCR compared with those with low Ki-67 expression (24% versus 7%, P = 0.019). Regarding C2P-RS, the high + intermediate group showed significantly higher pCR rates than the low group (24% versus 9%, P = 0.037) ( Table 3) . Univariate analyses also showed that ER, PR, HER2, Ki-67 expression and C2P-RS were significantly correlated with pCR (Table 4) . C2P-RS, cell cycle profiling risk score; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; N, node; NAC, neoadjuvant chemotherapy; P-FEC, paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide; PR, progesterone receptor; T, tumour. The evaluation of the relationship between the combination of C2P-RS and Ki-67 expression and pCR revealed that the pCR rate of the 'H/H' group, which was defined as having high + intermediate C2P-RS and high Ki-67 expression, was significantly higher (pCR rate, 29%, P = 0.039) than those of other categories, i.e. high + intermediate C2P-RS and low Ki-67 expression (H/L; pCR rate, 10%), low C2P-RS and high Ki-67 expression (L/H; pCR rate, 13%) and low C2P-RS and low Ki-67 expression (L/L; pCR rate, 4%) ( Table 5) . Univariate analysis showed a significant relationship between the combination of C2P-RS and Ki-67 and pCR [odds ratio (OR) 4.0, 95% confidence interval (CI) 1.4-11.1, P = 0.008]. The multivariate analysis showed that HER2 status (OR 2.8, 95% CI 1.0-8.1, P = 0.049) and the combination of C2P-RS and Ki-67 expression (OR 3.3, 95% CI 1.1-9.5, P = 0.031) were independent predictive indicators of pCR (Table 4) .
Annals of

discussion
BC is a heterogeneous disease with highly variable responses to therapy and clinical outcomes. This diversity is probably caused by the differences in tumour characteristics based on genetic or molecular alterations. Thus, it is necessary to assess and profile tumour characteristics accurately, to select the best strategy of treatment. A recent guideline for adjuvant therapy recommends the use of proliferation markers, as well as pathological characteristics, ER and HER2 status, in clinical practice for patients with early BCs [2] .
C2P-RS is a practical parameter, as it was originally devised to classify early BCs into three groups, i.e. groups with high, intermediate and low RS for relapse [13] . High C2P-RS implies that both CDK1 SA and CDK2 SA are high and that CDK2 SA predominates over CDK1 SA (Figure 1) . Therefore, we hypothesised that C2P-RS is a proliferation marker that is linked to growth speed. The finding that tumours with high C2P-RS had a significantly high growth rate compared with those with low C2P-RS in xenograft models of 14 human BC cell lines supports our hypothesis (T. Kiniwa, M. Klriyama, M. Shibayama, et al., unpublished data). The results of this study showing that a significant number of tumours with high + intermediate C2P-RS showed a good response to both paclitaxel and P-FEC compared with those with low C2P-RS also indicate that C2P-RS reflects tumour growth speed, as tumours with high growth speed are likely to respond to chemotherapy.
Ki-67 is universally expressed in proliferating cells with the exception of the G 0 phase, but it is not well known that the levels of Ki-67 depend on the cell cycle, i.e. they are low during the G 1 -S phase and increase progressively to reach a maximum during mitosis [9, 17] . The low expression of Ki-67 in the G 1 phase may affect the positivity of the signal and lead to interobserver variation. Ki-67 expression, however, is commonly determined as the percentage of positively stained tumour cells, regardless of expression intensity. Thus, Ki-67 expression is considered as representing the growth fraction but not the growth speed directly. The clinical relevance of Ki-67 expression seems to be attractive in terms of both its predictive and its prognostic values, although we have to consider some evidence of publication bias [4, 9, [18] [19] [20] . Most studies reported that high Ki-67 expression exhibited a significant correlation with a favourable response not only to chemotherapy but also to endocrine therapy [9, 19, 20] . In this study, high Ki-67 expression also had a significant relationship with high pCR rates compared with low Ki-67 expression. Conversely, recent meta-analyses addressing the prognostic value of Ki-67 showed that high Ki-67 expression was significantly associated with poor clinical outcomes in early BCs, whereas some studies showed no correlation between these parameters [4, 9, 18] . The correlation of Ki-67 expression with C2P-RS detected in this study was significantly positive but weak. In the Japanese retrospective multicentre study, the correlation between these two markers was also weakly positive but not significant (data not shown). Thus, C2P-RS and Ki-67 expression seem to represent two different aspects of proliferation (growth speed and growth fraction, respectively), suggesting that these two parameters should be used complementarily, and not competitively, to understand the proliferation status of tumours more accurately. This study demonstrated that the combination analysis of Ki-67 expression and C2P-RS yielded a stronger impact on the prediction of pCR after P-FEC compared with each of the parameters alone, which were assessed in the univariate analyses. Moreover, the multivariate analysis demonstrated that the combination of C2P-RS and Ki-67 expression, as well as HER2, was an independent predictive marker of pCR.
The recent development of high-throughput technologies can render gene expression profiling, e.g. intrinsic subtype, OncotypeDX Ò and MammaPrint Ò , successful in predicting clinical outcomes or identifying patients that need adjuvant chemotherapy [21] [22] [23] [24] . Furthermore, it has been studied whether these diagnostic tools can predict response to chemotherapy in the NAC setting. Rouzier et al. [25] reported that the basal-like and HER2+ subtypes based on gene expression profiles using fine needle aspiration (FNA) samples (N = 82) had significantly higher pCR rates (45%) than the luminal type (6%) in the neoadjuvant paclitaxel followed by 5-fluorouracil, doxorubicin and cyclophosphamide (P/FAC) regimen. This group also showed that gene expression profiling (74 markers) on FNA samples was a predictor of pCR to neoadjuvant P/FAC, and then they developed that system as the diagonal linear discriminant analysis classifier (30-probe set), showing high positive and negative predictive values to pCR (52% and 96%, respectively) [26, 27] . Gianni et al. [28] reported that the recurrence score calculated from the [29] demonstrated that no tumours with the good-prognosis signature of MammaPrint achieved pCR (0/23) to various NAC regimens, whereas a significant proportion of tumours with the poor-prognosis signature did (29/144, P = 0.015). Because C2P-RS has yet to be compared with these gene expression-based methods, it is unknown that C2P-RS has the additional value. But we believe that C2P-RS is unique in that it reflects the cell growth speed independently of Ki-67 index and cell growth speed is one of the most important determinants of response to chemotherapy. Thus, there still remains a possibility that C2P-RS might have the additive value to the gene expression-based methods. This issue needs to be clarified in a future study.
Gene expression profiles provide excellent performance to predict response to NAC, but it is not easy to use them in the practice. Thus, expression patterns of ER, PR and HER2 were used as surrogate markers of genomic molecular classification. Carey et al. [30] demonstrated that subtypes based on hormone receptor and HER2 status by IHC were significantly associated with pCR to doxorubicin and cyclophosphamide followed by taxane regimens, i.e. the pCR rates were 36% in HER2 subtype (ER2/PR2/HER2+), 27% in basal-like subtype (ER2/PR2/ HER22) and 7% in luminal subtypes (ER+ and/or PR+) (P = 0.01), similar to our present results (pCR rates: HER2, 43%; triple negative, 20%; luminal B, 14%; luminal A, 5%) (Table 3) . Recently, concurrent use of trastuzumab with NAC has become the standard care for HER2-positive diseases because several studies showed that such a therapy offered a great chance to achieve pCR compared with NAC alone [31, 32] . Thus, ideally predictive factors for HER2-positive tumours should be studied in patients treated with NAC and trastuzumab. However, such an evaluation could not be done in the present study because preoperative use of trastuzumab was not approved until April 2011 in Japan.
In conclusion, C2P-RS in needle biopsy samples may be a useful predictor of the response to P-FEC. The drawback of the C2P assay is the need for frozen samples, but recent developments in needle biopsy techniques can render sampling easy and accurate. The noninformative rate of this assay in needle biopsy samples seems to be acceptable (12.7%), although further improvement is desirable. We think it is practically not so difficult to spare just one core needle sample for this assay. C2P-RS, especially its combination with Ki-67, is a promising marker for the prediction of clinical outcomes and response to chemotherapy. However, these findings need to be validated for practical use using a larger number of patients on a multicentre basis.
acknowledgements
The authors thank Y. Naoi, T. Tanei, H. Yasojima, K. Ohshima and N. Oda for their excellent IHC work. They also thank T. Iwasaki for his continuous support of this project and helpful discussions. 
